MetaVia (NASDAQ:MTVA), a clinical-stage biopharmaceutical company focused on metabolic diseases, announced on April 10, 2026, that it has dosed the first patient in Part 3 of its Phase 1 clinical trial evaluating DA-1726.
The drug candidate is a dual oxyntomodulin analog acting on both GLP-1 and glucagon receptors, designed to address obesity through a multi-pathway approach.
The third part of the Phase 1 study is structured to evaluate the safety and efficacy of two distinct titration schedules over a 16-week period.
The trial will enroll 40 total subjects, split between a one-step titration cohort reaching a dose of 48 mg and a two-step titration cohort reaching 64 mg.
This phase aims to optimize the dosing regimen to minimize gastrointestinal side effects while maximizing metabolic impact.
DA-1726 distinguishes itself from current market leaders by targeting both the GLP-1 receptor, which regulates appetite, and the glucagon receptor, which increases energy expenditure and targets fat metabolism in the liver.
Early data released by the company showed promising results at the 48 mg dosage, including approximately 9% weight loss, significant reductions in waist circumference, and improved glycemic control.
MetaVia remains on track with its development timeline, projecting the release of topline data from Part 3 in the fourth quarter of 2026.
These results will be pivotal in determining the final dosing strategy for a planned Phase 2 study.